Tirzepatide and Alcohol: What Mayo Clinic Guidance Suggests

What the tirzepatide labels warn about

Tirzepatide is a dual GIP and GLP-1 receptor agonist, sold as Zepbound for weight management and Mounjaro for type 2 diabetes [1][2]. Its labeled warnings include acute pancreatitis, with instructions to stop the drug and begin appropriate management if pancreatitis is suspected, severe gastrointestinal reactions, acute gallbladder disease, and hypoglycemia when tirzepatide is used with insulin or an insulin secretagogue such as a sulfonylurea [1][2]. For that hypoglycemia warning, the label advises considering a lower dose of the insulin or sulfonylurea when tirzepatide is started [1][2].

The label also states that tirzepatide delays gastric emptying, which can affect the absorption of oral medicines [1].

Alcohol and pancreatitis

Alcohol misuse is a long-established risk factor for acute pancreatitis [3]. Tirzepatide carries its own labeled warning for acute pancreatitis [1][2]. Those are two separate facts, and together they do not establish how much risk an occasional drink, or heavy drinking, adds for someone taking tirzepatide.

How common the GI effects are

In the weight-management trials, Zepbound 15 mg produced nausea in 28%, vomiting in 13%, diarrhea in 23% and constipation in 11%, against 8%, 2%, 8% and 5% with placebo, over up to 72 weeks [1]. Adverse reactions led 6.7% of people on Zepbound 15 mg to stop treatment, compared with 3.4% on placebo [1].

Does tirzepatide change alcohol tolerance?

Alcohol tolerance means a lower effect of alcohol with repeated exposure [4]. We found no study that measured alcohol tolerance in people taking tirzepatide.